Stocks Health care BGLC
NASDAQ · Health careBioNexus Gene Lab Corp (BGLC)
BioNexus Gene Lab Corp brought in $3.1M of revenue over the twelve months to June 30, 2026, down 67.3% from a year earlier. It posted a net loss of $2.6M. In fiscal 2025 capital spending exceeded operating cash flow by $1.9M. At June 30, 2026 it held $1.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Watch BGLC in 60 secondsWhat BioNexus Gene Lab Corp does
BioNexus Gene Lab Corp is registered with the SEC under industry code SIC 8071 (Services-Medical Laboratories). Its shares trade on NASDAQ under the ticker BGLC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $7.4M | -$3M | n/a | -$1.9M |
| 2024 | $9.5M | -$1.6M | -$0.09 | -$2.3M |
| 2023 | $9.8M | -$2.6M | -$0.17 | -$2M |
| 2022 | $10.9M | -$356K | n/a | $551.8K |
| 2021 | $13.4M | $751.6K | n/a | $6K |
| 2020 | $11.4M | $1.1M | $0.01 | $131.1K |
Full financial statements: income, balance sheet and cash flow
Where BGLC ranks in Health care
Latest SEC filings
What BioNexus Gene Lab Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Activist stake (5% or more) SCHEDULE 13D
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 97% to $76.2K versus the same quarter last year; diluted EPS -$0.12 versus -$0.34.
- July 28, 2026Other event 8-K
- June 5, 2026Other event 8-K
- May 15, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 99% to $22.8K versus the same quarter last year; diluted EPS -$0.23 versus -$0.35.
- April 14, 2026Annual report 10-K · period to December 31, 2025Revenue fell 22% to $7.4M versus the prior year; net loss of $3M.
- March 31, 2026Late annual report notice NT 10-K
- March 17, 2026
- February 23, 2026Other event 8-K
- February 3, 2026Other event 8-K
Insider trades
What the people running BioNexus Gene Lab Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 5 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 13, 2026 | Low Jook YuenDirector | Received as pay | 16,129 | - |
| August 13, 2026 | Chong Set FuiChief Financial Officer | Received as pay | 96,774 | - |
| August 13, 2026 | Bin Abdul Hamid Muhammad AzrulDirector | Received as pay | 32,258 | - |
| August 13, 2026 | Yap Chee KeongDirector | Received as pay | 32,258 | - |
| August 13, 2026 | Tan Lee Su-LengChief Executive Officer, Director, 10% owner | Received as pay | 338,709 | - |
Who owns BGLC
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Tan Lee Su-Leng13D, may seek influence | 11.5% | August 14, 2026 |
Largest institutional holders
Insiders
5 insiders reported holding 517,389 shares in total, about $719.2K at the last price.
| Holder | Shares |
|---|---|
| Tan Lee Su-LengChief Executive Officer, Director, 10% owner | 338,709 |
| Chong Set FuiChief Financial Officer | 96,774 |
| Yap Chee KeongDirector | 32,258 |
| Bin Abdul Hamid Muhammad AzrulDirector | 32,258 |
| Low Jook YuenDirector | 17,390 |
Questions about BGLC
What does BioNexus Gene Lab Corp do?
BioNexus Gene Lab Corp is registered with the SEC under industry code SIC 8071 (Services-Medical Laboratories). Its shares trade on NASDAQ under the ticker BGLC.
Is BioNexus Gene Lab Corp profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $2.6M on revenue of $3.1M.
How much revenue does BioNexus Gene Lab Corp make?
Over the twelve months to June 30, 2026 BioNexus Gene Lab Corp reported revenue of $3.1M. That is 67.3% less than a year earlier.
When did BioNexus Gene Lab Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026.
Similar companies
Compare BGLC with
Follow BGLC
Get an email when BioNexus Gene Lab Corp files with the SEC: results, executive changes, material agreements and annual reports.
Follow BGLC: get an email when it filesWhere the numbers come from
Financial figures are the values BioNexus Gene Lab Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.